Are decentralized clinical trials the future?

In the last few years, there has been a dramatic increase in telemedicine, remote diagnoses, and prescribed treatment. The demand for these services highlighted their profound benefits, not only as a contingency but as a new modus operandi. But why stop at reactionary treatment?
 
Another consequence of the pandemic is the realization that we need to rethink the way we develop and deliver new drugs. Perhaps inspired by the rise of blockchain technology, the pharmaceutical industry has embraced the role of decentralization. As a result, many companies are now exploring the impact of Decentralized Clinical Trials (DCTs). New FDA guidance, increasing success of sponsorship, the removal of appointment conflicts, and streamlined data collection are just some of the major benefits.